Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2010
10/21/2010US20100266497 Internalizing Anti-CD74 Antibodies and Methods of Use
10/21/2010US20100266496 Anti-CD74 Immunoconjugates and Methods of Use
10/21/2010US20100266495 Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody
10/21/2010US20100266494 Treatment of cancer with novel anti-il13 monoclonal antibodies
10/21/2010US20100266493 Agonist antibodies against tshr
10/21/2010US20100266491 System for targeted delivery of therapeutic agents
10/21/2010US20100266490 Metalloproteinase Binding Proteins
10/21/2010DE202010010638U1 Nano-Hydrogele für die therapeutische und nichttherapeutische Behandlung, insbesondere zur Therapie von Stresszuständen und Regeneration Nano-hydrogels for the therapeutic and non-therapeutic treatment, in particular for the treatment of stress conditions and regeneration
10/21/2010CA2795906A1 Hpv particles and uses thereof
10/21/2010CA2761064A1 Imidazole substituted pyrimidines useful in the treatment of glycogen synthase kinase 3 related disorders such as alzheimer's disease
10/21/2010CA2759013A1 Combination immunotherapy compositions against cancer and methods
10/21/2010CA2759011A1 Antiadhesion agents
10/21/2010CA2758933A1 Histone modification patterns for clinical diagnosis and prognosis of cancer
10/21/2010CA2758916A1 Curcumin analogs as dual jak2/stat3 inhibitors and methods of making and using the same
10/21/2010CA2758913A1 Prion free nanoparticle compositions and methods of making thereof
10/21/2010CA2758823A1 Protein phosphatase 2a-activating agents
10/21/2010CA2758820A1 Targeted sustained-release microsphere of vascular occlusive agent containing sodium alginate and sorafenib, production method and use thereof
10/21/2010CA2758751A1 Antibodies against prostate specific membrane antigen
10/21/2010CA2758638A1 Imidazolidine-2,4-dione derivatives and use thereof as a medicament
10/21/2010CA2758630A1 Imidazolidine-2, 4-dioze derivatives, and use thereof as a cancer drug
10/21/2010CA2758614A1 Fluoro substituted pyrimidine compounds as jak3 inhibitors
10/21/2010CA2758542A1 Peptides targeting tnf family receptors and antagonizing tnf action, compositions, methods and uses thereof
10/21/2010CA2758473A1 Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia
10/21/2010CA2758359A1 Fused pyrrolopyridine derivative
10/21/2010CA2758229A1 Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
10/21/2010CA2758005A1 Methods of treating cancers with her3 antisense oligonucleotides
10/21/2010CA2757592A1 Bicyclic heterocyclyl derivatives as fgfr kinase inhibitors for therapeutic use
10/21/2010CA2757573A1 Substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carbonitriles and substituted 4-amino-5-benzoyl-2-(phenylamino)thiophene-3-carboxamides as tubulin polymerization inhibitors
10/21/2010CA2757382A1 Anti-fcrh5 antibodies and immunoconjugates and methods of use
10/21/2010CA2757326A1 Imidazo [1,2-a]pyridine derivatives as fgfr kinase inhibitors for use in therapy
10/21/2010CA2756973A1 Use of trifunctional bispecific antibodies for the treatment of tumors associated with cd133+/epcam+cancer stem cells
10/21/2010CA2756820A1 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
10/21/2010CA2756759A1 Imidazopyrazines for use as kinase inhibitors
10/21/2010CA2756570A1 Peptide ligands for clusterin and uses thereof
10/21/2010CA2755554A1 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
10/20/2010EP2241887A2 Diagnostics, drug screening and treatment for cancer
10/20/2010EP2241622A2 Human trk receptors and their derivatives
10/20/2010EP2241578A1 Anti-cldn6 antibody
10/20/2010EP2241577A1 Anti-CD37 antibodies
10/20/2010EP2241569A1 Thienopyridazine compounds, their preparations, pharmaceutical compositions and uses
10/20/2010EP2241565A1 Aurora kinase inhibitors compounds
10/20/2010EP2241557A1 Chinoxalin derivatives and use thereof for treating malignant and benign tumour illnesses
10/20/2010EP2241394A1 Gold nanoparticle composition, dna chip, near infrared absorbent, drug carrier for drug delivery system (dds), coloring agent, biosensor, cosmetic, composition for in vivo diagnosis and composition for therapeutic use
10/20/2010EP2241334A1 Method for determination of sensitivity to anti-cancer agent
10/20/2010EP2241333A1 Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
10/20/2010EP2241328A1 Interleukin-1 inhibitors in the treatment of diseases
10/20/2010EP2241324A1 Composition for use in a method for treating cancer.
10/20/2010EP2241313A1 Use of flavonoids to increase the bioavailability of hesperetin
10/20/2010EP2241309A2 Methods for encapsulation of proteins and adjuants in microspheres
10/20/2010EP2240517A1 Fdf03 antibodies and uses thereof
10/20/2010EP2240516A1 Methods and agents for improving targeting of cd138 expressing tumor cells
10/20/2010EP2240506A1 Inhibitors of iap
10/20/2010EP2240501A1 Hydroxy-bisphosphonic acid derivatives as vector for targeting bone tissue
10/20/2010EP2240488A1 Substituted imidazopyridazines useful as kinase inhibitors
10/20/2010EP2240483A1 Pyrimidyl cyclopentanes as akt protein kinase inhibitors
10/20/2010EP2240480A2 Derivatives of 2-heteroaroyl-imidazol(1,2-a)pyridine,preparation thereof and therapeutic application thereof
10/20/2010EP2240475A1 Thiazole derivatives used as pi 3 kinase inhibitors
10/20/2010EP2240466A1 Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
10/20/2010EP2240463A2 2-methylene-(20s,25r)-19,26-dinor-vitamin d analogs
10/20/2010EP2240455A1 Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
10/20/2010EP2240440A2 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs
10/20/2010EP2240439A1 (20s)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin d analogs
10/20/2010EP2240438A1 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin d analogs
10/20/2010EP2240203A1 Alpha 5 - beta 1 antibodies and their uses
10/20/2010EP2240194A1 Treatment of melanoma with alpha thymosin peptides in combination with a kinase inhibitor
10/20/2010EP2240174A1 Pharmaceutical compositions comprising n-ý2-(diethylamino)ethyl¨-5-ý(5-fluoro-1,2- dihydro-2-oxo-3h-indol-3-ylidene)methyl¨-2,4-dimethyl-1h-pyrrole-3-carboxamide
10/20/2010EP2240171A2 Inhibitors of carbonic anhydrase ix
10/20/2010EP2240169A2 Cytostatic composition
10/20/2010EP2240168A2 Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with metabolic modulators
10/20/2010EP2240028A1 Organic compounds
10/20/2010EP2125794B1 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
10/20/2010EP2102173B1 Pyrimidyl derivatives as protein kinase inhibitors
10/20/2010EP2049491B1 Heteroaryl compounds useful as inhibitors of e1 activating enzymes
10/20/2010EP1984331B1 Pyrrolidine derivatives as erk inhibitors
10/20/2010EP1957060B1 Cancer treatment using fts and 2-deoxyglucose
10/20/2010EP1951653B1 Salicylic acid derivatives
10/20/2010EP1899320B1 Substituted pyrr0lidin-2-0nes , piperidin-2-0nes and isothiazolidine-1, 1-dioxides, their use as kv1 .5 potassium channel blockers and pharmaceutical preparations comprising them
10/20/2010EP1811998B1 Triazoles useful as inhibitors of protein kinases
10/20/2010EP1687338B1 Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses thereof
10/20/2010EP1594491B1 Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
10/20/2010EP1407269B1 A method for diagnosing a person having multiple sclerosis
10/20/2010EP1383513B1 Tumor therapy with sindbis virus-based vectors
10/20/2010EP1366366B1 Compositions and methods for the diagnosis, treatment and prevention of steroid hormone responsive cancers
10/20/2010CN1854313B Method for diagnosing non-small cell lung cancers
10/20/2010CN101868478A Inhibition of macrophage-stimulating protein receptor (RON) and methods of treatment thereof
10/20/2010CN101868465A Solid forms comprising n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith
10/20/2010CN101868464A Thienopyrimidiene derivatives as PI3k inhibitors
10/20/2010CN101868453A Inhibitors of the interaction between MDM2 and P53
10/20/2010CN101868447A Method of making and administering quinoline derivatives as anti-cancer agents
10/20/2010CN101868243A Aromatase inhibitor
10/20/2010CN101868227A Lyophilized pharmaceutical composition with improved stability containing taxane derivatives, and method of manufacturing the same
10/20/2010CN101864452A Double-specificity anti-tumor recombinant adenovirus and construction method and application thereof
10/20/2010CN101864400A Specific recombinant adenoviruses, preparation thereof and use thereof
10/20/2010CN101864398A Monoclonal antibody of anti-gonadotropin-releasing hormone receptor and application thereof
10/20/2010CN101864373A Microorganism strain for producing prodigiosin and application thereof
10/20/2010CN101864078A Polyethyleneimine-chitosan-octadecanoic acid grafting, preparation and application
10/20/2010CN101863997A Method for preparing hojothuria leucospilota polysaccharide
10/20/2010CN101863985A Recombinant human fusion Tat cytoglobulin and application thereof in treating liver cancer
10/20/2010CN101863984A Prostatic cancer therapeutic vaccine modified on surface of GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor)/TNF (Tumor Necrosis Factor)-alpha membrane
10/20/2010CN101863960A Preparation method of cetrorelix
1 ... 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 ... 2211